Cargando…
The Impact of Highly Effective Treatment in Pediatric-Onset Multiple Sclerosis: A Case Series
Introduction: Pediatric-onset multiple sclerosis (POMS) is characterized by high inflammatory disease activity. Our aim was to describe the treatment sequencing and report the impact highly effective disease-modifying treatment (HET) had on disease activity. Materials and Methods: Five consecutive p...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688929/ https://www.ncbi.nlm.nih.gov/pubmed/36360426 http://dx.doi.org/10.3390/children9111698 |
_version_ | 1784836394167828480 |
---|---|
author | Immovilli, Paolo De Mitri, Paola Bazzurri, Veronica Vollaro, Stefano Morelli, Nicola Biasucci, Giacomo Magnifico, Fabiola Marchesi, Elena Lombardelli, Maria Lara Gelati, Lorenza Guidetti, Donata |
author_facet | Immovilli, Paolo De Mitri, Paola Bazzurri, Veronica Vollaro, Stefano Morelli, Nicola Biasucci, Giacomo Magnifico, Fabiola Marchesi, Elena Lombardelli, Maria Lara Gelati, Lorenza Guidetti, Donata |
author_sort | Immovilli, Paolo |
collection | PubMed |
description | Introduction: Pediatric-onset multiple sclerosis (POMS) is characterized by high inflammatory disease activity. Our aim was to describe the treatment sequencing and report the impact highly effective disease-modifying treatment (HET) had on disease activity. Materials and Methods: Five consecutive patients with POMS were administered HET following lower efficacy drug or as initial therapy. Data on treatment sequencing, relapses and MRIs were collected during the follow-up. Results: Our patients had an average age of 13.8 years (range 9–17) at diagnosis and 13.4 years (range 9–16) at disease onset, and 2/5 (40%) POMS were female. The pre-treatment average annualized relapse rate was 1.6 (range 0.8–2.8), and the average follow-up length was 5 years (range 3–7). A total of 2/5 (40%) patients were stable on HET at initial therapy, and 3/5 (60%) required an escalation to more aggressive treatment, even if two of them had been put on HET as initial treatment. Four out of five patients (80%) had No Evidence of Disease Activity-3 status (NEDA-3) at an average follow-up of 3 years (range 2–5). Conclusion: It has been observed that in a recent time period all the cases had prompt diagnosis, early HET or escalation to HET with a good outcome in 80% of the cases. |
format | Online Article Text |
id | pubmed-9688929 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96889292022-11-25 The Impact of Highly Effective Treatment in Pediatric-Onset Multiple Sclerosis: A Case Series Immovilli, Paolo De Mitri, Paola Bazzurri, Veronica Vollaro, Stefano Morelli, Nicola Biasucci, Giacomo Magnifico, Fabiola Marchesi, Elena Lombardelli, Maria Lara Gelati, Lorenza Guidetti, Donata Children (Basel) Article Introduction: Pediatric-onset multiple sclerosis (POMS) is characterized by high inflammatory disease activity. Our aim was to describe the treatment sequencing and report the impact highly effective disease-modifying treatment (HET) had on disease activity. Materials and Methods: Five consecutive patients with POMS were administered HET following lower efficacy drug or as initial therapy. Data on treatment sequencing, relapses and MRIs were collected during the follow-up. Results: Our patients had an average age of 13.8 years (range 9–17) at diagnosis and 13.4 years (range 9–16) at disease onset, and 2/5 (40%) POMS were female. The pre-treatment average annualized relapse rate was 1.6 (range 0.8–2.8), and the average follow-up length was 5 years (range 3–7). A total of 2/5 (40%) patients were stable on HET at initial therapy, and 3/5 (60%) required an escalation to more aggressive treatment, even if two of them had been put on HET as initial treatment. Four out of five patients (80%) had No Evidence of Disease Activity-3 status (NEDA-3) at an average follow-up of 3 years (range 2–5). Conclusion: It has been observed that in a recent time period all the cases had prompt diagnosis, early HET or escalation to HET with a good outcome in 80% of the cases. MDPI 2022-11-05 /pmc/articles/PMC9688929/ /pubmed/36360426 http://dx.doi.org/10.3390/children9111698 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Immovilli, Paolo De Mitri, Paola Bazzurri, Veronica Vollaro, Stefano Morelli, Nicola Biasucci, Giacomo Magnifico, Fabiola Marchesi, Elena Lombardelli, Maria Lara Gelati, Lorenza Guidetti, Donata The Impact of Highly Effective Treatment in Pediatric-Onset Multiple Sclerosis: A Case Series |
title | The Impact of Highly Effective Treatment in Pediatric-Onset Multiple Sclerosis: A Case Series |
title_full | The Impact of Highly Effective Treatment in Pediatric-Onset Multiple Sclerosis: A Case Series |
title_fullStr | The Impact of Highly Effective Treatment in Pediatric-Onset Multiple Sclerosis: A Case Series |
title_full_unstemmed | The Impact of Highly Effective Treatment in Pediatric-Onset Multiple Sclerosis: A Case Series |
title_short | The Impact of Highly Effective Treatment in Pediatric-Onset Multiple Sclerosis: A Case Series |
title_sort | impact of highly effective treatment in pediatric-onset multiple sclerosis: a case series |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688929/ https://www.ncbi.nlm.nih.gov/pubmed/36360426 http://dx.doi.org/10.3390/children9111698 |
work_keys_str_mv | AT immovillipaolo theimpactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT demitripaola theimpactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT bazzurriveronica theimpactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT vollarostefano theimpactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT morellinicola theimpactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT biasuccigiacomo theimpactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT magnificofabiola theimpactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT marchesielena theimpactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT lombardellimarialara theimpactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT gelatilorenza theimpactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT guidettidonata theimpactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT immovillipaolo impactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT demitripaola impactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT bazzurriveronica impactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT vollarostefano impactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT morellinicola impactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT biasuccigiacomo impactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT magnificofabiola impactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT marchesielena impactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT lombardellimarialara impactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT gelatilorenza impactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries AT guidettidonata impactofhighlyeffectivetreatmentinpediatriconsetmultiplesclerosisacaseseries |